|
J Biol Chem, Vol. 274, Issue 31, 21665-21672, July 30, 1999
Yeast and Rat Coq3 and Escherichia coli UbiG
Polypeptides Catalyze Both O-Methyltransferase Steps in
Coenzyme Q Biosynthesis*
Wayne W.
Poon,
Robert J.
Barkovich,
Adam Y.
Hsu,
Adam
Frankel,
Peter T.
Lee,
Jennifer N.
Shepherd ,
David C.
Myles, and
Catherine F.
Clarke§
From the Department of Chemistry and Biochemistry and the Molecular
Biology Institute, University of California,
Los Angeles, California 90095
 |
ABSTRACT |
Ubiquinone (coenzyme Q or Q) is a lipid that
functions in the electron transport chain in the inner mitochondrial
membrane of eukaryotes and the plasma membrane of prokaryotes.
Q-deficient mutants of Saccharomyces cerevisiae harbor
defects in one of eight COQ genes (coq1-coq8)
and are unable to grow on nonfermentable carbon sources. The
biosynthesis of Q involves two separate O-methylation steps. In yeast, the first O-methylation utilizes
3,4-dihydroxy-5-hexaprenylbenzoic acid as a substrate and is thought to
be catalyzed by Coq3p, a 32.7-kDa protein that is 40% identical to the
Escherichia coli O-methyltransferase, UbiG. In this study,
farnesylated analogs corresponding to the second
O-methylation step, demethyl-Q3 and Q3, have been chemically synthesized and used to study Q
biosynthesis in yeast mitochondria in vitro. Both yeast and
rat Coq3p recognize the demethyl-Q3 precursor as a
substrate. In addition, E. coli UbiGp was purified and
found to catalyze both O-methylation steps. Futhermore,
antibodies to yeast Coq3p were used to determine that the Coq3
polypeptide is peripherally associated with the matrix-side of the
inner membrane of yeast mitochondria. The results indicate that one
O-methyltransferase catalyzes both steps in Q biosynthesis in eukaryotes and prokaryotes and that Q biosynthesis is carried out
within the matrix compartment of yeast mitochondria.
 |
INTRODUCTION |
Ubiquinone is an essential lipid in the electron transport chain
that is found in the inner mitochondrial membranes of eukaryotes and in
the plasma membrane of prokaryotes (1). The structure of
Q1 consists of a quinone head
group and a hydrophobic isoprenoid tail that can vary in length
depending on the species in which it is found. The quinone group
undergoes reversible single electron transfers, interchanging between
the quinone, semiquinone, and hydroquinone, whereas the isoprenoid tail
functions to anchor Q in the membrane. In eukaryotes, Q functions to
shuttle electrons from either Complex I or Complex II to Complex
III/bc1 complex. The transfer of electrons from
Q to the bc1 complex is coupled to
proton-translocation via the Q cycle mechanism that was first proposed
by Mitchell (2). A number of studies support such a mechanism (for a
review, see Ref. 1) including the recently determined complete
structure of the bc1 complex (3).
The redox properties of Q also allow it to function as a lipid soluble
antioxidant. Q functions by either directly scavenging lipid peroxyl
radicals (4) or indirectly reducing -tocopherol radicals to
regenerate -tocopherol (5, 6). Additionally, Q protects cells from
oxidative damage generated by the autoxidation of polyunsaturated fatty
acids (7). Q is found in many eukaryotic intracellular membranes,
including the plasma membrane, where, in conjunction with a plasma
membrane electron transport system, it functions to scavenge ascorbate
free radicals (8, 9). In the plasma membrane of prokaryotes, Q
participates in the maintenance of the enzymatic activity of DsbA/DsbB
disulfide bond forming proteins (10), and Q-deficient Escherichia
coli strains are hypersensitive to thiol exposure (11).
In both eukaryotes and prokaryotes, the first committed step in the
biosynthesis of Q begins with the precursors
p-hydroxybenzoic acid (pHB) and isoprenoid diphosphate, in
which the isoprenoid is covalently attached to the aromatic ring. The
pathway derives from the characterization of accumulating Q
biosynthetic intermediates in studies with Saccharomyces
cerevisiae (12) and E. coli (13) Q-deficient mutants.
In yeast, Q mutant strains have been classified into eight
complementation groups, and five COQ genes have been characterized. The COQ1 and COQ2 genes encode the
polyprenyl diphosphate synthase and the pHB:polyprenyldiphosphate
transferase, respectively (14, 15). The COQ3 gene encodes
the O-methyltransferase thought to catalyze the first
O-methylation step (16, 17), and the COQ5 gene
encodes the C-methyltransferase in Q biosynthesis (18, 19).
Finally, the COQ7 gene encodes a protein that localizes to
yeast mitochondria (20) and is required for the final monooxygenase step in Q biosynthesis (21), but has also been implicated in aging and
development in C. elegans (22).
The Q biosynthetic pathway in E. coli has been carefully
worked out by analyzing ubi mutant strains (23) for
accumulating Q intermediates at the blocked metabolic steps, and many
of the bacterial genes have been characterized (24). These include ubiC, ispB, and ubiA, which encode the chorismate
pyruvate lyase (25), octaprenyl synthase (26), and the
pHB:octaprenyltransferase (27), respectively. Genes encoding the
hydroxylase (ubiH) (28) and the
O-methyltransferase (ubiG) (29, 30) have also
been reported, and recently, the gene encoding the
C-methyltransferase gene in E. coli was
characterized (ubiE) (31). Although eukaryotes and
prokaryotes share many similar steps in Q biosynthesis, the pathway
diverges after the prenylation step (16, 32, 33). In prokaryotes,
decarboxylation, hydroxylation, and methylation follow prenylation,
whereas in eukaryotes, the sequence is hydroxylation, methylation, and
then decarboxylation. Recent evidence suggests that the Q biosynthetic
pathway in higher eukaryotes is similar to S. cerevisiae. Both rat and human COQ3 and COQ7
homologs can complement the corresponding defect in yeast
(34-36).2
We have been examining the enzymes that catalyze the
O-methylations in prokaryotic and eukaryotic Q biosynthesis.
E. coli strains harboring null mutations in the
ubiG gene are defective in the first
O-methylation step (conversion of compound 1 to
2, Fig. 1) (30). Surprisingly, strains harboring leaky mutant alleles of ubiG accumulate demethyl-Q8,
the last intermediate in Q biosynthesis (Fig. 1, compound
5), and are unable to carry out the last
O-methylation step (37, 38). The analysis of both null and
leaky mutant alleles of ubiG suggested that the ubiG gene product was required for both of the
O-methylations in Q biosynthesis (30). Unlike the E. coli ubi mutants, analysis of accumulating Q intermediates in
yeast coq mutants has been less informative. Yeast strains
harboring coq3, coq4, coq5,
coq6, coq7, or coq8 mutant alleles all
accumulate the same single predominant intermediate,
3-hexaprenyl-4-hydroxybenzoic acid (39, 40). For this reason, it has
often been instructive to compare the yeast COQ genes with
the E. coli ubi gene counterparts. The encoded amino acid
sequence of yeast COQ3 is 40% identical with the E. coli UbiG protein and both sequences contain the four motifs
identified in a large family of
S-adenosyl-L-methionine
(AdoMet)-dependent methyltransferases (41). In this study,
in vitro assays have been developed that facilitate the
study the catalytic role of both the UbiG and Coq3 proteins in
O-methylation reactions. These assays demonstrate that each
enzyme is active at all three O-methylation steps shown in
Fig. 1. Mitochondria subfractionation studies indicate that the Coq3
polypeptide is a peripherally associated inner membrane protein,
located on the matrix side. The results presented suggest that both the
first and last O-methylation steps in the yeast Q
biosynthetic pathway occur within the mitochondria matrix compartment.
 |
EXPERIMENTAL PROCEDURES |
General Synthetic Procedures--
All reagents were used as
received from Aldrich Chemical Co. unless otherwise noted. Unless
specified as dry, the solvents were of unpurified reagent grade.
Diethyl ether was distilled from sodium using benzophenone as an
indicator. All air- or water-sensitive reactions were carried out under
positive pressure of argon. Reactions were followed by TLC using
Whatman precoated plates of silica gel 60 with fluorescent indicator.
Reactions forming quinones were followed by leucomethylene blue stain.
Normal phase flash chromatography was performed on Davisil Grade 643 silica gel (230-400 mesh). NMR spectra were measured on a Bruker
ARX400 or ARX500 MHz spectrometer. Low and high resolution mass spectra
were determined on a VG Autospec. Synthetic procedures used to generate
farnesylated analogs of compounds 1, 2, 3, and 4 (Fig. 1) were described previously (30,
42, 43).
3-Hydroxy-4,5-dimethoxy-2-acetyltoluene (8)--
In a glove bag
under N2, AlCl3 (3.29 g, 24.7 mmol) was placed
into a 100-ml round-bottomed flask. The flask was sealed and transferred to an argon atmosphere before anhydrous ether (15 ml) was
slowly added, followed by 3,4,5-trimethoxytoluene (7) (2.8 ml, 16.6 mmol) and acetyl chloride (1.5 ml, 17.3 mmol). The reaction
mixture turned dark and murky and was stirred for 20 h at room
temperature. Following the addition of water (10 ml) and concentrated
HCl (1 ml), the mixture was extracted with ether (three times, 15 ml).
The combined ether layers were extracted with 1 M NaOH
(three times, 20 ml), and the resulting aqueous layers were acidified
by dropwise addition of concentrated HCl and then cooled in an ice-bath
for 1 h. The product crystallized and was filtered using a Buchner
funnel with Whatman No. 50 paper to give 1.56 g (44.6% yield) of
pale yellow solid 8. 1H NMR (CDCl3,
400 MHz) 2.54 (s, 3H), 2.62 (s, 3H), 3.86 (s, 3H), 3.91 (s, 3H), 6.31 (s,
3H), 11.97 (s, 3H); 13C NMR
(CDCl3, 100 MHz) 204.33, 156.62, 155.87, 135.91, 134.46, 117.15, 106.90, 60.63, 55.84, 33.00, 24.37; LRMS m/z
(relative intensity) EI 210.1 (72), 195.1 (100), 180.0 (17); HRMS
m/z calculated for
C11H14O4 (M+),
210.089067; found, 210.089209.
2,3-Dihydroxy-4,5-dimethoxytoluene (9)--
Compound
8 (180 mg, 0.86 mmol) was dissolved in a solution of sodium
hydroxide (68 mg, 1.7 mmol) and water (4 ml). Hydrogen peroxide (0.12 ml, 30% in H2O) was added dropwise to the reaction mixture
via an addition funnel over 10 min. The mixture was then heated at
45 °C for 2 h. Five minutes after the heating was initiated,
the solution darkened from a pale yellow to a deep violet. The reaction
was quenched by the addition of 1 M HCl (15 ml) and then
extracted with dichloromethane (3 × 20 ml). The combined organic
layers were dried over Na2SO4, filtered, and
concentrated, by rotary evaporation. Flash chromatography using
hexane:ethyl acetate (9:1) gave yellow solid 9 (80 mg, 51%
yield). 1H NMR (CDCl3, 400 MHz) 3.22 (s,
3H), 3.23 (s, 3H), 3.89 (s, 3H),
4.95 (s, 1H), 5.61 (s, 1H), 6.26 (s, 1H); 13C NMR
(CDCl3, 100 MHz) 145.36, 136.39, 136.31, 134.06, 118.80, 105.41, 61.13, 56.25, 15.46; LRMS m/z (relative intensity)
EI 184.1 (100), 169.0 (96), 154.1 (74), 139.0 (20), 126.0 (25), 111.0 (83); HRMS m/z calculated for
C9H12O4 (M+),
184.073485; found, 184.073559.
2-Hydroxy-3-methoxy-6-methyl-1,4-benzoquinone or Fumigatin
(10)--
Compound 9 (73.4 mg, 0.40 mmol) was dissolved
in a 1:1 mixture of dichloromethane:acetonitrile (4 ml). A solution of ammonium cerium (IV) nitrate (655.4 mg, 1.20 mmol) in
dichloromethane:acetonitrile (1:1, 2 ml) was then added dropwise to the
reaction mixture over 5 min. The solution color changed from yellow to
a turbid maroon. Stirring was continued for 5 min before the reaction
was quenched by the addition of 10 ml of water. The reaction mixture
was extracted with dichloromethane (three times, 15 ml) and the
combined organic layers were concentrated by rotary evaporation. The
crude residue was redissolved in ether (20 ml) and then treated with 1 M NaHCO3 (20 ml). The aqueous layer became a
bright violet color. Following two washes with ether, the aqueous layer
was slowly acidified using concentrated HCl until the solution color
changed from deep violet to orange. The aqueous layer was then
extracted three times with ether. The combined ether extracts were
dried over MgSO4, filtered, and concentrated by rotary
evaporation to give fumigatin (56.5 mg, 84.4% yield), a red
crystalline solid. 1H NMR (CDCl3, 400 MHz) 2.06 (d, J = 1.7 Hz, 3H), 4.09 (s, 3H),
6.39 (q, J = 1.7 Hz, 1H), 6.44 (br. s, 1H); 13C NMR
(CDCl3, 100 MHz) 184.73, 183.45, 141.56, 140.02, 137.51, 132.44, 60.35, 14.93; LRMS m/z (relative intensity)
EI 168.0 (100), 127.0 (48), 97.0 (33); HRMS m/z calculated
for C8H8O4 (M+),
168.042536; found, 168.042259.
5-Farnesyl-2-hydroxy-3-methoxy-6-methyl-1,4-benzoquinone or
Demethyl-Q3 (5)--
The Freidel-Crafts
allylation of 10 was performed as described (44) with the
following modifications. Fumigatin (30.1 mg, 0.177 mmol) was dissolved
in 1:1 ether:ethanol (6 ml), and then
Na2S2O4 (10% in H2O)
was added dropwise to the stirred solution until decolorization of the
mixture was achieved. Ether (5 ml) was added to the decolorized mixture
and the organic layer was washed three times with brine, dried over
MgSO4, and concentrated in vacuo. The resulting
hydroquinone of fumigatin was dissolved in freshly distilled 1, 4-dioxane (6 ml) under an argon atmosphere. Trans-trans-farnesol (118 mg, 0.53 mmol) was added to the
solution, followed by BF3OEt2 (79.6 ml, 0.63 mmol), and the reaction was allowed to proceed for 18 h at room
temperature. The reaction mixture was washed with brine and extracted
three times with ether. The combined organic layers were dried over
MgSO4, filtered, and concentrated in vacuo. The
crude product was dissolved in ether (10 ml) and treated with excess
FeCl3 in a 1:1 mixture of water:methanol for 30 min. The
resulting mixture was extracted three times with ether, dried over
MgSO4, filtered, and concentrated by rotary evaporation.
The crude product was purified on a Florisil column with the following
gradient system: 4:1 hexane/ethyl acetate, 1:1 hexane/ethyl acetate,
100% ethyl acetate, 4:1 hexane/ethyl acetate, 4:1 hexane/ethyl acetate
with 1% glacial acetic acid. As described by Moore and Folkers (44),
the desired product (demethyl-Q3) was retained as a bright
purple compound at the top of the column until the final wash
containing 1% glacial acetic acid was performed. Upon treatment with
acetic acid, the color of the desired compound changed from purple to
red-orange, and it was then eluted from the column. A yellow-orange oil
(5) (18.5 mg, 28% yield) was obtained. 1H NMR
(CDCl3, 500 MHz) 1.57 (s, 3H), 1.59 (s,
3H), 1.67 (s, 3H), 1.74 (s, 3H),
1.98 (m, 8H), 2.04 (s, 3H), 3.20 (d, J = 7 Hz, 2H),
4.06 (s, 3H), 4.92 (t, J = 1 Hz, 1H), 5.06 (m, 2H),
6.48 (br. s, 1H); 13C NMR (CDCl3, 125 MHz) 185.14, 183.16, 143.36, 139.17, 137.82, 137.04, 136.16, 135.22, 131.30, 124.29, 123.81, 118.64, 60.26, 39.68, 26.74, 26.42, 35.68, 25.42, 17.65, 16.33, 16.01, 11.59; LRMS m/z (relative intensity) EI
372.2 (40), 267.0 (11), 236.1 (58), 221.1 (100), 183.1 (48), 162.0 (20), 121.1 (30); HRMS m/z calculated for
C23H32O4 (M+),
372.230403; found, 372.230060.
Strains and Growth Media--
The strains of S. cerevisiae used in the in vitro studies were JM45
(MATa, leu2-3, leu2-112, ura3-52, trp1-289, his4-580) (45), a parent strain possessing Q synthesis, and JM45 coq3 (MATa,
leu2-3, leu2-112, ura3-52, trp1-289,
his4-580, coq3::LEU2) (17). The yeast strains used in
the localization studies were wild-type, W3031A (MATa, leu2-3,
leu2-112, ura3-1, trp1-1, his3-11, ade2-1) (46), and the
coq3 strain, CC3031B (MAT , leu2-3, leu2-112, ura3-1,
trp1-1, his3-11, ade2-1, coq3 ::LEU2) (7). The
E. coli strain used was DH5 , which was obtained from Life
Technologies, Inc. Growth media for yeast were prepared as described
(47) and included YPD (1% yeast extract, 2% peptone, 2% dextrose), YPG (1% yeast extract, 2% peptone, 3% glycerol), YPGal (1% yeast extract, 2% peptone, 2% galactose) and SD-Ura (0.18% yeast nitrogen base without amino acids, 2% dextrose, 0.14%
NaH2PO4, 0.5%
(NH4)2SO4), with complete
supplement minus uracil. The complete supplement was modified so that
the final concentration of each component was as follows: 80 mg/liter,
adenine sulfate, uracil, tryptophan, histidine, methionine, and
cysteine; 40 mg/liter, arginine and tyrosine; 120 mg/liter, leucine; 60 mg/liter, isoleucine, lysine, and phenylalanine; 100 mg/liter, glutamic
acid and aspartic acid; 150 mg/liter, valine; 200 mg/liter, threonine;
and 400 mg/liter, serine). S. cerevisiae and E. coli were grown at 30 and 37 °C, respectively.
Plasmid Construction--
DNA constructions were performed as
described (48). pTHG was constructed to express UbiG as a fusion
protein with a 33-amino acid N-terminal extension, containing 6 His
residues (His6-UbiG) to provide for metal affinity column
purification. A DNA segment containing the complete ubiG ORF
(851-1572) was generated by a polymerase chain reaction with Vent DNA
Polymerase (New England Biolabs) using pRPB (29) as the DNA template
with the primers, pGB,
(5'-GCGGATCCGATGAATGCCGAAAAATCGCCGGTA-3') and pCC4K (30). The resulting 723-base pair product was inserted after digestion with
BamHI and KpnI into the similarly digested vector
pTrcHisB (Invitrogen) to generate pTHG. The plasmids, pQM and pCHQ3,
were described previously (30).
Purification of His6-UbiG Fusion
Protein--
Purification of His6 UbiG was done with the
TALON metal affinity resin (CLONTECH) as described
by the manufacturer. The E. coli strain, DH5 :pTHG,
containing the His6-UbiG was grown in LB+Amp (50 µg/ml)
and induced with isopropyl-1-thio- -D-galactopyranoside (final concentration, 0.4 mM), and cells were disrupted by
the French press method. His6-UbiG was purified on a TALON
column under native conditions. The resin was washed with 15 mM imidazole to remove nonspecifically bound proteins,
His6-UbiG was eluted from the resin with 250 mM
imidazole, and the imidazole was removed by dialysis against 0.05 M sodium phosphate, pH 7.0.
Generation of Yeast Coq3p Antibodies--
A plasmid encoding a
glutathione S-transferase-Coq3p fusion protein was
constructed by subcloning the 1.7-kilobase EcoRI fragment of
pRS12A (17) into the EcoRI site of pGEX-2T (Amersham
Pharmacia Biotech). The fusion protein contained amino acids 64-316 of
yeast Coq3p as a C-terminal fusion to glutathione
S-transferase and was produced in E. coli and the
insoluble fraction was separated by preparative SDS-polyacrylamide gel
electrophoresis. The 50-kDa fusion protein was visualized by copper
staining (49) and eluted from the gel by diffusion (50). The protein
was injected into rabbits, and antibodies were affinity purified
according to standard techniques (51).
In Vitro Assays--
Assays for O-methyltransferase
activities were determined with the three synthetic methyl-acceptors,
compounds 1, 3, and 5. Stocks of
1, 3, and 5 were stored undiluted at
20 °C under argon. In assays with either 1 or
3, the substrates were redissolved into methanol, and each
reaction mixture (250 µl) contained 0.05 M sodium
phosphate, pH 7.0, 1.0 mM ZnSO4, and 50 µl of
crude yeast mitochondria (0.25-0.50 mg of protein) (52) or purified
E. coli protein, His6-UbiG (1.2 ng). The final
concentration of compound 1 or 3 in each assay
was 50 µM unless otherwise stated. Reactions were started
with the addition of
S-adenosyl-L-[methyl-3H]methionine
to a final concentration of 60 µM (NEN Life Science Products, 84.1 Ci/mmol; specific activity was adjusted to 560 mCi/mmol
with unlabeled S-adenosyl-L-methionine). The
concentration of S-adenosyl-L-methionine was
determined by its absorbance at 256 nm ( 15, 200 M 1 cm 1) (53). After incubation,
the reaction was stopped by addition of glacial acetic acid (5 µl),
and the lipids were extracted with chloroform, concentrated and
analyzed by high performance liquid chromatography as described (30).
In vitro assays with compound 5 were the same as
described above except that 5 was redissolved into hexane
and NADH (3 mM) was included in the assays with yeast
mitochondria in order to form the hydroquinone. In assays with purified
His6-UbiG, 5 was reduced with 10% sodium
dithionite, and prior to addition, the sodium dithionite was removed by
centrifugation. Following incubation, reactions were terminated by the
addition of excess ammonium cerium (IV) nitrate to oxidize the
methylated product, and lipids were extracted with hexane (two times,
0.5 ml), concentrated, and analyzed by high performance liquid
chromatography as described above.
Localization of Yeast Coq3p--
Yeast (W3031A or CC3031B) was
grown in YPGal media to saturation density (A600 ~ 10.0), and a crude mitochondria fraction was isolated and further
purified over a linear Nycodenz gradient as described (52).
Subfractionation of purified mitochondria was carried out by generating
mitoplasts as described (20), and fractionation of mitoplasts was
accomplished by either sonication (four 10-s pulses, 20% duty cycle,
2.5 output setting Sonifier W350, Branson Sonic Power Co.) or alkaline
carbonate extraction (54, 55). Protease protection experiments were
carried out as described (56). Equal amounts of protein as determined
by the BCA method (Pierce) were separated by electrophoresis on 12% polyacrylamide gels (57) and subsequently transferred to Hybond ECL
nitrocellulose (Amersham Pharmacia Biotech). Western analysis with the
ECL system was carried out as described by Amersham Pharmacia Biotech
except that 10 mM Tris, pH 8.0, 154 mM NaCl,
0.1% Triton X-100 was used as the Western washing buffer. The primary
antibodies were used at the following dilutions: -Coq3, 1:1,000; Hsp
60, 1:10,000; F1 ATPase, 1:10,000; cytochrome
c1, 1:400; cytochrome b2,
1:5000. Horseradish peroxidase-linked secondary antibodies to rabbit
IgG (Amersham Pharmacia Biotech) were used in a 1:1000 dilution.
 |
RESULTS |
Chemical Synthesis of Ubiquinone Biosynthetic Analogs as
Methyl-acceptor Substrates for in Vitro Assays--
We have chemically
synthesized farnesylated analogs of Q-intermediates
1-4 in Fig. 1
(n = 3) (30, 43). Fig. 2
shows the synthetic scheme for the last O-methylation
substrate, demethyl-Q3 (compound 5). Fumigatin
(compound 10) was generated by a modification of the
synthesis described by Baker and Raistrick (58). Friedel-Crafts
allylation (59) of the hydroquinone form of 10 with a prenyl
tail forms demethyl-Q3 (Fig. 2, compound 5). A
tin-assisted allylation of Qo was carried out as described
by Naruta (60) to form the farnesylated product standard for the final
O-methylation step, Q3 (Fig. 1, compound
6).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 1.
O-Methyltransferase steps in
ubiquinone biosynthesis. The proposed biosynthetic pathway for Q
in eukaryotes and prokaryotes is thought to diverge following
prenylation of p-hydroxybenzoic acid and in both cases
involves two O-methylation steps. In E. coli, the
first O-methylation step requires UbiG, and involves the
O-methylation of 2-polyprenyl-6-hydroxyphenol
(compound 1), to form 2-polyprenyl-6-methoxyphenol
(compound 2). In eukaryotes, the first
O-methylation step requires the Coq3 polypeptide for the
conversion of 3,4-dihydroxy-5-polyprenylbenzoic acid (compound
3) to 3-methoxy-4-hydroxy-5-polyprenylbenzoic acid
(compound 4). In both eukaryotes and prokaryotes, the
second O-methylation of
2-polyprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinol
(compound 5) forms ubiquinol-n
(compound 6). E. coli, n = 8; S. cerevisiae, n = 6.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2.
Chemical synthesis of
demethyl-Q3. Details of the synthesis are described
under "Experimental Procedures."
|
|
Coq3p Is Required for Both O-Methylation Steps in Ubiquinone
Biosynthesis--
Our previous O-methyltransferase in
vitro assays indicated that multiple steps may be catalyzed by the
same enzyme (30). Specifically, in vitro assays with cell
free extracts of E. coli showed that the ubiG
gene was required for the methylation of both compounds 1 and 3. These results indicated that UbiG was involved in
both O-methylation steps of Q biosynthesis, because Leppik
et al. (38) showed that UbiG was required for the
methylation of 5 to 6. By analogy, it seemed likely that the COQ3 gene product may also be required for
both O-methylation steps in eukaryotic Q biosynthesis. To
test this idea, in vitro O-methylation assays were performed
with the synthetic Q-intermediate analog 5 (n = 3) as substrate. The methyl donor was
[methyl-3H]AdoMet, and mitochondria were isolated from
three yeast strains: 1) a wild-type respiratory competent strain
(JM45), 2) the coq3 deletion mutant harboring the plasmid
vector as a control (JM45 coq3:pQM), and 3) a rescued mutant with a
multicopy plasmid encoding yeast COQ3 expressed from the
CYC1 promoter (JM45 coq3:pCHQ3) (Fig. 3A). Mitochondria from
respiratory competent yeast produced a radioactive product that
co-migrated with the Q3 standard (compound 6) on
reverse-phase high performance liquid chromatography (Fig.
3A) (fraction 17). This activity (40.2 pmol/mg of protein/h) required the reducing agent, NADH, because omitting NADH resulted in no
O-methyltransferase activity. No activity was detected in mitochondria isolated from a coq3 null mutant
(JM45 coq3:pQM). However, transformation of this strain with the
COQ3 gene (JM45 coq3:pCHQ3) restored activity (161 pmol/mg
of protein/h). Thus, a functional Coq3 polypeptide is required for both
the first (43) and second O-methylation steps in yeast Q
biosynthesis.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Coq3p is required for the
O-methylation of demethyl-Q3 (compound 5)
and 2-farnesyl-6-hydroxyphenol (compound 3). Crude mitochondrial
extracts were prepared from JM45 (wild-type (WT), and
), JM45 coq3:pQM (vector control, ), and JM45 coq3:pCHQ3
(COQ3 gene on a multiple copy plasmid, ) as described,
and incubated with demethyl-Q3 (compound 5)
(A) or 2-farnesyl-6-hydroxyphenol (1 mM)
(compound 3) (B), and
S-adenosyl-L-[methyl-3H]methionine.
In A, 3 mM NADH was included in all incubations
except for that indicated ( ). Following incubation for 1 h,
lipids were extracted and analyzed by reverse-phase high performance
liquid chromatography (Alltech Lichrosorb C-18, 5 mm, 4.6 × 250 mm) with 9:1 methanol/water as the mobile phase and a flow rate of 1 ml/min.
|
|
Similar in vitro assays were carried out to determine
whether Coq3p was required for the methylation of the farnesylated
analog of the E. coli substrate (compound 1). As
shown in Fig. 3B, mitochondria from wild-type yeast
contained high activity (22.8 pmol/mg of protein/h) and produced a
radiolabeled product that co-migrated with the farnesylated analog of
2. This activity was not detected in the coq3
null mutant (JM45 coq3:pQM), but the activity (16.3 pmol/mg of
protein/h) was again restored when mitochondria from the rescued strain
were examined (JM45 coq3:pCHQ3). These results suggest that the Coq3p
O-methyltransferase is capable of methylating multiple Q
precursor analogs.
Conservation of Function between Yeast and Rat O-Methyltransferase
Activity--
To examine whether the in vitro assays
described above could be used to study Q biosynthetic steps in higher
eukaryotes, the plasmid pAB2 (34), which contains the rat
COQ3 cDNA, was transformed into JM45 coq3.
Mitochondria were isolated from this strain and assayed for
O-methylation activity with farnesylated analogs of 1 (Fig. 4A),
5 (Fig. 4B) or 3 (Fig. 4C). In each case, the radioactive methylated products were detected that
eluted with chemically synthesized methylated products (2, 6, and 4, respectively). The activities were
174.2, 42.5, and 54.1 pmol/mg of protein/h, respectively. These assays demonstrate that farnesylated analogs of Q biosynthetic intermediates can be used to study Q biosynthesis in higher eukaryotes. Additionally, these results indicate that both O-methylation steps in rats
also require Coq3p and that this O-methyltransferase has a
wide substrate specificity.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
The rat COQ3 gene restores
O-methyltransferase activity in coq3
null mutant yeast. Yeast crude mitochondrial extracts were
prepared from JM45 coq3:pAB2 (rat COQ3 gene) and in
vitro O-methylation assays were carried out as
described in Fig. 5. Three different analogs of Q-intermediates were
used as substrates: A, 2-farnesyl-6-hydroxyphenol (compound
1); B, demethyl-Q3 (compound
5); C, 3,4-dihydroxy-5-farnesylbenzoic acid
(compound 3). In each assay, O-methyltranferase
activity required the rat COQ3 gene because no activity was
detected in its absence (see Fig. 3, A and B).
The elution positions of methylated farnesylated standards
(2, 6, and 4) are indicated.
|
|
The UbiG Polypeptide Catalyzes Both O-Methylation Steps in E. coli
Q Biosynthesis--
A direct test of the hypothesis that Coq3p and
UbiGp catalyze both O-methyltransferase steps required
preparations of the pure polypeptides. To facilitate purification, the
UbiG polypeptide was expressed as a fusion protein containing an
N-terminal His6 sequence. The N-terminal extension does not
interfere with activity, as the expression of this fusion protein in
the E. coli ubiG disruption mutant GD1 (30) restores growth
on succinate and results in a 50-fold increase in
1:O-methyltransferase activity in E. coli whole cell extracts. The His6-UbiG fusion protein
was purified as described under "Experimental Procedures" and used in in vitro O-methylation assays. Farnesylated analogs of
1 (Fig. 5A),
5 (Fig. 5B) or 3 (Fig. 5C)
were tested as methyl-acceptor substrates. In each case, radioactive
methylated products were detected that co-eluted with chemically
synthesized methylated products 2 (813 µmol/mg of
protein/h), 6 (275 µmol/mg of protein/h), and 4 (2, 290 µmol/mg of protein/h), respectively. Methylation of
5 required that it be reduced prior to addition (data not
shown). Thus, the purified UbiG polypeptide is sufficient for the
catalysis of both O-methylation steps in the biosynthesis of
Q in E. coli, and is capable of methylating the eukaryotic
substrate.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 5.
Purified His6-UbiG catalyzes all
O-methylation steps in Q biosynthesis. In
vitro O-methyltransferase assays were carried out with the
purified His6-UbiG enzyme using the three synthetic analogs
previously described. A, 2-farnesyl-6-hydroxyphenol
(compound 1); B, the hydroquinone form of
demethyl-Q3 (compound 5); C,
3,4-dihydroxy-5-farnesylbenzoic acid (compound 3). The
elution position of the methylated products are indicated
(2, 6, and 4).
|
|
Subcellular Localization of the Coq3 Polypeptide--
Previous
work showed that the yeast Coq3p precursor was imported into
mitochondria in vitro, and a mitochondrial membrane potential was required for processing to the mature (protease resistant) form (30). To determine the location of Coq3p in yeast,
affinity purified polyclonal antibodies were prepared against Coq3p.
Fractions of cytosol, crude mitochondria, and Nycodenz-purified mitochondria were prepared from both the CC3031B null mutant strain and
the wild-type parental strain, W3031A. Immunoblot analysis (Fig.
6A) of each fraction indicated
that the 33-kDa polypeptide (corresponding to the mature Coq3p) was
detected only in the mitochondrial fractions of wild-type yeast but not
in the coq3 null mutant.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 6.
Coq3p is a peripheral mitochondrial inner
membrane protein. A, yeast cells from a wild-type
strain, W3031A (lanes 2, 4, and 6), or a
coq3 null mutant, CC3031B (lanes 1, 3, and
5), were grown to saturation, and the cells were collected,
lysed, and fractionated by standard methods. Crude mitochondria were
then purified over Nycodenz gradients (see under "Experimental
Procedures"). Samples (5 µg of protein) from the cytoplasmic
fractions (lanes 1 and 2), the crude
mitochondrial fractions (crude mito) (lanes 3 and
4), and the Nycodenz purified mitochondrial fractions
(pure mito) (lanes 5 and 6) were
separated by SDS-polyacrylamide gel electrophoresis. The gel was
transferred to nitrocellulose for Western analysis by chemiluminescence
detection using antibodies to Coq3p( Coq3p) and the mitochondrial
marker protein, cytochrome c1 (64).
B, mitoplasts from yeast strain W3031A were generated and
either sonicated or treated with 0.1 M
Na2CO3, pH 11.5, incubated on ice, and
centrifuged as described (see under "Experimental Procedures"). 10 µg of protein from each resultant supernatant (S) and
pellet (P) fraction were analyzed by SDS-polyacrylamide gel
electrophoresis, transferred for Western analysis, and probed via
chemiluminescence detection using antibodies to Coq3p, cytochrome
c1, Hsp 60, or F1 ATPase.
C, intact mitochondria (left four lanes),
mitoplasts, or mitoplasts containing 1% Triton X-100 were treated with
increasing concentrations of proteinase K (0, 10, 25, 50, and 100 µg/ml). Samples of each (1 µg) were analyzed by SDS-polyacrylamide
gel electrophoresis, transferred for Western analysis, and probed via
chemiluminescence detection using antibodies to Coq3p, cytochrome
b2, F1 ATPase, or Hsp 60.
|
|
Submitochondrial Localization of the Coq3 Polypeptide--
To
determine the submitochondrial localization of Coq3p, yeast
mitochondria were further fractionated (54). Purified mitochondria from
W3031A were subjected to treatment with hypotonic buffer, which
disrupts the outer membrane and releases soluble proteins of the
intermembrane space while keeping the inner membrane intact. Western
analysis of the soluble fraction indicated that Coq3p remained
associated with the pellet (mitoplast fraction) and did not co-purify
with the intermembrane space marker, cytochrome b2 (data not shown). Mitoplasts were further
fractionated either by sonication, which releases soluble matrix
proteins into the supernatant following centrifugation, or by
extraction with alkaline carbonate, which releases both soluble and
peripherally bound membrane proteins into the supernatant (61). As
shown in Fig. 6B, Coq3p was released by alkaline carbonate
extraction, which was similar to the matrix marker, Hsp60 (62), and the
peripheral inner membrane protein F1 ATPase (63). In
contrast, these conditions did not release the integral membrane
marker, cytochrome c1 (64). However, sonication
conditions that release Hsp60 into the supernatant fraction, did not
release Coq3p or the peripheral membrane marker, F1 ATPase. These results indicate that Coq3p is a
peripheral membrane protein similar to the F1 ATPase.
To determine whether Coq3p is associated with the matrix-side or the
outside of the inner membrane of yeast mitochondria, purified
mitochondria or mitoplasts were subjected to increasing concentrations
of proteinase K and then subjected to Western analysis (Fig.
6C). The results indicate that Coq3p was protected from protease treatment in both intact mitochondria and mitoplasts. This
degree of protease protection is also a property of the inner membrane
marker, F1 ATPase, and Hsp60, a matrix marker. However, cytochrome b2, an intermembrane space protein,
was fully digested in mitoplasts as expected. Additionally, treatment
of mitoplasts with 1% Triton X-100 detergent rendered all proteins
protease-sensitive. These data indicate that the Coq3 polypeptide is
peripherally associated with the matrix side of the inner membrane of mitochondria.
 |
DISCUSSION |
This study demonstrates that both O-methylation steps
in Q biosynthesis are catalyzed by the same enzyme. The in vitro
O-methylation assays employ farnesylated analogs of compounds
1, 3, and 5 as substrates,
[methyl-3H]AdoMet, and the detection of
radiolabeled methylated products corresponding to compounds
2, 4, and 6. Such assays have been
performed with isolated yeast mitochondria containing yeast Coq3p (Fig.
3) (43), yeast mitochondria containing rat Coq3p (Fig. 4), cell free
extracts of E. coli (30), and with purified UbiG polypeptide
(Fig. 5). In each case, the presence of either Coq3 or UbiG is required
to observe in vitro O-methylation, and both Coq3p and UbiG
methylate all three substrates.
These assays showed that methylation of 5 by yeast
mitochondria required NADH. A similar requirement was observed for the
O-methylation of 5 by E. coli extracts
(38) and rat liver mitochondria (65). It is likely that NADH provides
the reducing equivalents for the generation of the hydroquinone.
Accordingly, the purified UbiG O-methyltransferase also
requires 5 to be present in the reduced form (Fig. 5). All
three compounds thus contain a similar catechol functional group.
The O-methylation of the farnesylated analogs of
Q-intermediates by yeast and rat Coq3 and E. coli UbiG is
interesting because the naturally occurring quinone species in each of
these organisms is different. In yeast, the prenyl tail length
(n) is 6; in E. coli, n = 8; and
in rats, n = 9 or 10. Additionally, Q biosynthesis can
be restored in coq3 null mutants by the human
COQ3 homolog.2 Therefore, it is likely that the
human Coq3p recognizes the farnesylated species as well. Such
promiscuity is not uncommon in Q biosynthesis because the
pHB:polyprenyldiphosphate transferase from rats can recognize other
aromatic precursors (66, 67), and in yeast, it can utilize polyprenyl
groups ranging from n = 5 to n = 10 (68). Also, the C-methyltransferase enzyme in E. coli carries out steps in both Q and menaquinone biosynthesis
(31).
A low degree of substrate specificity is also seen for the enzyme,
catechol-O-methyltransferase (COMT). COMT is known to
methylate numerous neurotransmitters (dopamine, norepinephrine, and
epinephrine), their hydroxylated derivatives, and other analogs (69).
Both COMT and Coq3/UbiG enzymes require a divalent cation, but
comparison of their primary amino acid sequences fails to reveal any
homology aside from the AdoMet-dependent methyltransferase
motifs. The recent structure of COMT from rat liver (70) provides
insight into the mechanism for the O-methylation reaction.
The O-methyltransferase in Q biosynthesis may rely on a
similar mechanism as the one reported for COMT.
Subcellular fractionation localizes Coq3p to the mitochondria. These
data confirm and extend previous results that demonstrated import of
the yeast Coq3p precursor into the mitochondria in vitro, and showed that such import required a membrane potential (30). The N
terminus of the precursor Coq3p contains a putative mitochondrial leader sequence (71, 72), which is proteolytically cleaved upon import
to produce the mature form (30). The submitochondrial localization of
Coq3p was also determined (Fig. 6). Mitochondrial fractionation and
protease protection experiments coupled with Western analysis
demonstrated that Coq3p was a peripherally associated protein of the
inner mitochondrial membrane. This evidence localizes Coq3p and
therefore the site for both O-methylation steps of Q biosynthesis within the mitochondrial matrix.
The intracellular site(s) for Q biosynthesis in eukaryotes is still not
elucidated. Studies in yeast show that the hexaprenyldiphosphate synthase and the pHB:polyprenyldiphosphate transferase activities reside in mitochondria (73), and both proteins contain typical mitochondrial leader sequences (13, 14). Recently, the yeast COQ5 gene encoding the C-methyltransferase was
localized to mitochondria (18, 19). The Coq7 (Cat5/Clk-1) polypeptide,
which is required in one or more hydroxylase steps in Q biosynthesis
(21), was also found in the mitochondria (20). The COQ3 gene
product from Arabidopsis was recently localized to the
membrane fraction of mitochondria (74). Also, it was previously shown
that the O-methyltransferase responsible for converting
5 to Q in rat liver was localized to the inner membrane of
the mitochondria (65). However, studies with rat liver show Q
biosynthesis occurring in the endoplasmic reticulum-Golgi system
(75-77). These results conflict with earlier studies that indicate
that Q is synthesized solely in the mitochondria (65, 78, 79). The
ability of the rat Coq3p to rescue a yeast coq3 mutant (34)
suggests that it must be present in the mitochondria of yeast and of
rats as well. This conclusion is further supported by the rescue of a
coq3 mutant with the E. coli homolog,
ubiG, on a single copy plasmid that required that UbiG
contain a mitochondrial targeting sequence at the N terminus (30).
Although redistribution of the mitochondrial targeted protein fumarase
has been reported (80), this requires a cotranslational insertion
mechanism that is not required for Coq3p.
UbiG can function as a soluble enzyme. Earlier studies showed that UbiG
activity was associated with the E. coli plasma membrane, but it could be solubilized (30, 38). This differs from yeast and
higher eukaryotes, in which the corresponding homolog, Coq3, appears
tightly associated with the inner mitochondrial membrane. Our attempts
to solubilize Coq3p activity by sonication or detergent treatments have
been unsuccessful. However, activity for the second O-methyltransferase in rat liver mitochondria was
solubilized by treatment with Triton X-100 (65). The native molecular
weight for the enzyme in those studies was not determined.
Unlike UbiG, which is readily purified as an active soluble enzyme,
overexpression of Coq3p in E. coli produced no active enzyme
and failed to rescue the ubiG growth defect in E. coli. These observations suggest that Coq3p may require additional
polypeptides that 1) may function to keep it peripherally associated
with the membrane, or 2) may function in a possible uncharacterized
regulatory manner not present in prokaryotes. In either case, these
additional polypeptides evidently are required for activity. The
evidence for a possible complex in Q biosynthesis in eukaryotes is
further supported by the lack of O-methyltransferase
activity in other coq null
mutants3 that may lack the
required "additional" proteins. In Nocardia lactamdurans, the biosynthesis of cephamycin C involves the
interaction of two proteins, a hydroxylase and a methyltransferase,
encoded by the genes cmcI and cmcJ, respectively,
that are required for function (81). The sequence of hydroxylation and
methylation in cephamycin C biosynthesis is similar to Q biosynthesis.
The possibility of a protein complex involved in Q biosynthesis will require further study.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Alexander Tzagoloff, Michael
Yaffe, Martin Horst, and Gottfried Schatz for generously donating the
antibodies in this work. We thank Drs. Kym Faull and Richard Stevens at
the University of California, Los Angeles Mass Spectrometry facility for the analysis of the Q analog precursors. We also thank members of
the Clarke laboratory for input on this study, especially Tanya Jonassen and Grigory Belogrudov for help with the mitochondrial localization. We also thank Lawrence Kong, Dr. Steven Clarke, and Dr.
Kym Faull for helpful contributions.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grant GM45952 (to C. F. C.) and United States Public Health Service National Service Award GM07185 (to W. W. P.)The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Current address: Dept. of Chemistry, AD Box 15, Gonzaga
University, E. 502 Boone Ave., Spokane, WA 99258-0001
§
To whom correspondence should be addressed: Dept. of Chemistry and
Biochemistry, University of California, Los Angeles, 607 Charles E. Young Drive East, Los Angeles, CA 90095-1569. Tel.: 310-825-0771; Fax:
310-206-5213; E-mail: cathy@mbi.ucla.edu.
2
T. Jonassen and C. F. Clarke, unpublished data.
3
A. Y. Hsu, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
Q, ubiquinone or
coenzyme Q;
pHB, p-hydroxybenzoic acid;
AdoMet, S-adenosyl-L-methionine;
demethyl-Qn, demethyl-Q or
5-polyprenyl-2-hydroxy-3-methoxy-6-methyl-1,4-benzoquinone, where
n indicates the number of isoprenoids;
COMT, catechol
O-methyltransferase.
 |
REFERENCES |
| 1.
|
Brandt, U.,
and Trumpower, B.
(1994)
Crit. Rev. Biochem. Mol. Biol.
29,
165-197[Medline]
[Order article via Infotrieve]
|
| 2.
|
Mitchell, P.
(1976)
J. Theor. Biol.
62,
327-367[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Iwata, S.,
Lee, J. W.,
Okada, K.,
Lee, J. K.,
Iwata, M.,
Rasmussen, B.,
Link, T. A.,
Ramaswamy, S.,
and Jap, B. K.
(1998)
Science
281,
64-71[Abstract/Free Full Text]
|
| 4.
|
Ernster, L.,
and Forsmark-Amdree, P.
(1993)
Clin. Invest.
71,
S60-S65[Medline]
[Order article via Infotrieve]
|
| 5.
|
Kagan, V.,
Serbinova, E.,
and Packer, L.
(1990)
Biochem. Biophys. Res. Commun.
169,
851-857[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Bowry, V. W.,
Mohr, D.,
Cleary, J.,
and Stocker, R.
(1995)
J. Biol. Chem.
270,
5756-5763[Abstract/Free Full Text]
|
| 7.
|
Do, T.,
Schultz, J. R.,
and Clarke, C. F.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7534-7539[Abstract/Free Full Text]
|
| 8.
|
Santos-Oscana, C.,
Cordoba, F.,
Crane, F. L.,
Clarke, C. F.,
and Navas, P.
(1998)
J. Biol. Chem.
273,
8099-8105[Abstract/Free Full Text]
|
| 9.
|
Santos-Ocana, C.,
Villalba, J. M.,
Cordoba, F.,
Padilla, S.,
Crane, F. L.,
Clarke, C. F.,
and Navas, P.
(1998)
J. Bioenerg. Biomembr.
30,
465-475[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Kobayashi, T.,
Kishigami, S.,
Sone, M.,
Inokuchi, H.,
and Mogi, T.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11857-11862[Abstract/Free Full Text]
|
| 11.
|
Zeng, H.,
Snavely, I.,
Zamorano, P.,
and Javor, G. T.
(1998)
J. Bacteriol.
180,
3681-3685[Abstract/Free Full Text]
|
| 12.
|
Olson, R. E.,
and Rudney, H.
(1983)
Vitam. Horm.
40,
1-43[Medline]
[Order article via Infotrieve]
|
| 13.
|
Gibson, F.
(1973)
Biochem. Soc. Trans.
1,
317-326
|
| 14.
|
Ashby, M. N.,
and Edwards, P. A.
(1990)
J. Biol. Chem.
265,
13157-13164[Abstract/Free Full Text]
|
| 15.
|
Ashby, M. N.,
Kutsunai, S. Y.,
Ackerman, S.,
Tzagoloff, A.,
and Edwards, P. A.
(1992)
J. Biol. Chem.
267,
4128-4136[Abstract/Free Full Text]
|
| 16.
|
Goewert, R. R.,
Sippel, J. C.,
and Olson, R. E.
(1981)
Biochemistry
20,
4217-4223[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Clarke, C. F.,
Williams, W.,
and Teruya, J. H.
(1991)
J. Biol. Chem.
266,
16636-16644[Abstract/Free Full Text]
|
| 18.
|
Barkovich, R. J.,
Shtanko, A.,
Shepherd, J. A.,
Lee, P. T.,
Myles, D. C.,
Tzagoloff, A.,
and Clarke, C. F.
(1997)
J. Biol. Chem.
272,
9182-9188[Abstract/Free Full Text]
|
| 19.
|
Dibrov, E.,
Robinson, K. M.,
and Lemire, B. D.
(1997)
J. Biol. Chem.
272,
9175-9181[Abstract/Free Full Text]
|
| 20.
|
Jonassen, T.,
Proft, M.,
Randez-Gil, F.,
Schultz, J. R.,
Marbois, B. N.,
Entian, K.-D.,
and Clarke, C. F.
(1998)
J. Biol. Chem.
273,
3351-3357[Abstract/Free Full Text]
|
| 21.
|
Marbois, B. N.,
and Clarke, C. F.
(1996)
J. Biol. Chem.
271,
2995-3004[Abstract/Free Full Text]
|
| 22.
|
Ewbank, J. J.,
Barnes, T. M.,
Lakowski, B.,
Lussier, M.,
Bussey, H.,
and Hekimi, S.
(1997)
Science
275,
980-983[Abstract/Free Full Text]
|
| 23.
|
Gibson, F.,
and Young, I. G.
(1978)
Methods Enzymol.
53,
600-609[Medline]
[Order article via Infotrieve]
|
| 24.
|
Meganathan, G.
(1996)
in
Esherichia coli and Salmonella, Cellular and Molecular Biology
(Neidhardt, F. C.
, Curtiss, R.
, Lin, E. C. C.
, Low, K. B.
, Magasanik, B.
, Reznikoff, W. S.
, Riley, M.
, Schaechter, M.
, and Umbarger, H. E., eds), 2nd Ed., Vol. 1
, pp. 642-656, American Society for Microbiology, Washington D. C.
|
| 25.
|
Siebert, M.,
Severin, K.,
and Heide, L.
(1994)
Microbiology
140,
897-904[Abstract/Free Full Text]
|
| 26.
|
Okada, K.,
Minehira, M.,
Zhu, X.,
Suzuki, K.,
Nakagawa, T.,
Matsuda, H.,
and Kawamukai, M.
(1997)
J. Bacteriol.
179,
3058-3060[Abstract/Free Full Text]
|
| 27.
|
Wu, G.,
Williams, H. D.,
Gibson, F.,
and Poole, R. K.
(1993)
J. Gen. Microbiol.
139,
1795-1805[Abstract/Free Full Text]
|
| 28.
|
Nakahigashi, K.,
Miyamoto, K.,
Nishimura, K.,
and Inokuchi, H.
(1992)
J. Bacteriol.
174,
7352-7359[Abstract/Free Full Text]
|
| 29.
|
Wu, G.,
Williams, H. D.,
Zamanian, M.,
Gibson, F.,
and Poole, R. K.
(1992)
J. Gen. Microbiol.
138,
2101-2112[Abstract/Free Full Text]
|
| 30.
|
Hsu, A. Y.,
Poon, W. W.,
Shepherd, J. A.,
Myles, D. C.,
and Clarke, C. F.
(1996)
Biochemistry
35,
9797-9806[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Lee, P. T.,
Hsu, A. Y.,
Ha, H. T.,
and Clarke, C. F.
(1997)
J. Bacteriol.
179,
1748-1754[Abstract/Free Full Text]
|
| 32.
|
Cox, G. B.,
Young, I. G.,
McCann, L. M.,
and Gibson, F.
(1969)
J. Bacteriol.
99,
450-458[Abstract/Free Full Text]
|
| 33.
|
Goewert, R. R.,
Sippel, J. C.,
Grimm, M. F.,
and Olson, R. E.
(1981)
Biochemistry
20,
5611-5616[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Marbois, B. N.,
Hsu, A. Y.,
Pillai, R.,
Colicelli, J.,
and Clarke, C. F.
(1994)
Gene
138,
213-217[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Jonassen, T.,
Marbois, B. N.,
Kim, L.,
Chin, A.,
Xia, Y.-R.,
Lusis, A. J.,
and Clarke, C. F.
(1996)
Arch. Biochem. Biophys.
330,
285-289[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
| Vajo, Z., King, L. M., Jonassen, T., Wilkin, D. J., Ho, N., Minnich,
A., Clarke, C. F., and Francomano, C. A. (1999) Mamm.
Genome, in press
|
| 37.
|
Stroobant, P.,
Young, I. G.,
and Gibson, F.
(1972)
J. Bacteriol.
109,
134-139[Abstract/Free Full Text]
|
| 38.
|
Leppik, R. A.,
Stroobant, P.,
Shineberg, B.,
Young, I. G.,
and Gibson, F.
(1976)
Biochim. Biophys. Acta
428,
146-156[Medline]
[Order article via Infotrieve]
|
| 39.
|
Poon, W. W.,
Marbois, B. N.,
Faull, K. K.,
and Clarke, C. F.
(1995)
Arch. Biochem. Biophys.
320,
305-314[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Poon, W. W.,
Do, T. Q.,
Marbois, B. N.,
and Clarke, C. F.
(1997)
Mol. Aspects Med.
18,
s121-s127
|
| 41.
|
Kagan, R. M.,
and Clarke, S.
(1994)
Arch. Biochem. Biophys.
310,
417-427[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Shepherd, J. A.
(1995)
Synthesis of CoenzymeQ Biosynthetic Intermediates as Substrates for Q Methyltransferase in Vitro Assays.M.Sc. thesis
, University of California, Los Angeles
|
| 43.
|
Shepherd, J. A.,
Poon, W. W.,
Myles, D. C.,
and Clarke, C. F.
(1996)
Tetrahedron Lett.
37,
2395-2398[CrossRef]
|
| 44.
|
Moore, H. W.,
and Folkers, K.
(1966)
J. Am. Chem. Soc.
88,
564-567[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
McEwen, J. E.,
Ko, C.,
Kloeckner-Gruissem, B.,
and Poyton, R. O.
(1986)
J. Biol. Chem.
261,
11872-11879[Abstract/Free Full Text]
|
| 46.
|
Repetto, B.,
and Tzagoloff, A.
(1989)
Mol. Cell. Biol.
9,
2695-2705[Abstract/Free Full Text]
|
| 47.
|
Adams, A.,
Gottschling, D. E.,
Kaiser, C. A.,
and Stearns, T.
(1997)
Methods in Yeast Genetics
, pp. 145-149, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 48.
|
Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., Struhl, K., Albright, L. M., Coen, D. M., Varki, A., and Janssen, K.
(eds)
(1997)
Current Protocols in Molecular Biology
, Wiley Interscience, New York
|
| 49.
|
Garfin, D. E.
(1990)
Methods Enzymol.
182,
425-441[Medline]
[Order article via Infotrieve]
|
| 50.
|
Harrington, M. G.
(1990)
Methods Enzymol.
182,
488-495[Medline]
[Order article via Infotrieve]
|
| 51.
|
Harlow, E.,
and Lane, D.
(1988)
Antibodies: A Laboratory Manual
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 52.
|
Glick, P. S.,
and Pon, L. A.
(1995)
Methods Enzymol.
260,
213-233[Medline]
[Order article via Infotrieve]
|
| 53.
|
Dawson, R. M. C.,
Elliott, D. C.,
Elliott, W. H.,
and Jones, K. M.
(1986)
Data for Biochemical Research
, 3rd Ed.
, pp. 2-3, Oxford University Press, New York
|
| 54.
|
Yaffe, M. P.
(1991)
Methods Enzymol.
194,
627-643[Medline]
[Order article via Infotrieve]
|
| 55.
|
Jarosch, E.,
Tuller, G.,
Daum, G.,
Walkherr, M.,
Voskova, A.,
and Schweyen, R. J.
(1996)
J. Bio. Chem.
271,
17219-17225[Abstract/Free Full Text]
|
| 56.
|
Koehler, C. M.,
Merchant, S.,
Oppliger, W.,
Schmid, K.,
Jarosch, E.,
Dolfini, L.,
Junne, T.,
Schatz, G.,
and Tokatlidis, K.
(1998)
EMBO J.
17,
6477-6486[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Baker, W.,
and Raistrick, H.
(1941)
J. Am. Chem. Soc.
1941,
670-672[CrossRef]
|
| 59.
|
Shunk, C. H.,
McPherson, J. F.,
and Folkers, K.
(1966)
J. Org. Chem.
31,
1638-1639[Medline]
[Order article via Infotrieve]
|
| 60.
|
Naruta, Y.
(1980)
J. Org. Chem.
45,
4097-4104[CrossRef]
|
| 61.
|
Fujiki, A.,
Hubbard, A. L.,
Fowler, S.,
and Lazarow, P. B.
(1982)
J. Cell Biol.
93,
97-102[Abstract/Free Full Text]
|
| 62.
|
Reading, D. S.,
Hallber, R. L.,
and Myer, A. M.
(1989)
Nature
337,
655-659[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Chen, W.-J.,
and Douglas, M. G.
(1987)
Cell
49,
651-658[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Ohashi, A.,
Gibson, J.,
Gregor, I.,
and Schatz, G.
(1982)
J. Biol. Chem.
257,
13042-13047[Abstract/Free Full Text]
|
| 65.
|
Houser, R. M.,
and Olson, R. E.
(1977)
J. Biol. Chem.
252,
4017-4021[Abstract/Free Full Text]
|
| 66.
|
Nambudiri, A. M. D.,
Brockman, D.,
Alam, S. S.,
and Rudney, H.
(1977)
Biochem. Biophys. Res. Commun.
76,
282-288[CrossRef]
|
| 67.
|
Alam, S. S.,
Nambudiri, A. M. D.,
and Rudney, H.
(1975)
Arch. Biochem. Biophys.
171,
183-190[CrossRef][Medline]
[Order article via Infotrieve]
|
| 68.
|
Okada, K.,
Kainou, T.,
Matsuda, H.,
and Kawamukai, M.
(1998)
FEBS Lett.
431,
241-244[CrossRef][Medline]
[Order article via Infotrieve]
|
| 69.
|
Kaakkola, S.,
Gordin, A.,
and Mannisto, P. T.
(1994)
Gen. Pharmacol.
25,
813-825[Medline]
[Order article via Infotrieve]
|
| 70.
|
Vidgren, J.,
Svensson, L. A.,
and Liljas, A.
(1994)
Nature
368,
354-358[CrossRef][Medline]
[Order article via Infotrieve]
|
| 71.
|
Hartl, F.-U.,
Pfanner, N.,
Nicholson, D. W.,
and Neupert, W.
(1989)
Biochim. Biophys. Acta
988,
1-45[Medline]
[Order article via Infotrieve]
|
| 72.
|
Neupert, W.
(1997)
Annu. Rev. Biochem.
66,
863-917[CrossRef][Medline]
[Order article via Infotrieve]
|
| 73.
|
Casey, J.,
and Threlfall, D. R.
(1978)
Biochim. Biophys. Acta
530,
487-502[Medline]
[Order article via Infotrieve]
|
| 74.
|
Avelange-Macherel, M.-H.,
and Joyard, J.
(1998)
Plant J.
14,
203-213[CrossRef][Medline]
[Order article via Infotrieve]
|
| 75.
|
Kalen, A.,
Norling, B.,
Appelkvist, E. L.,
and Dallner, G.
(1987)
Biochim. Biophys. Acta
926,
70-78[Medline]
[Order article via Infotrieve]
|
| 76.
|
Kalen, A.,
Appelkvist, E. L.,
Chojnacki, T.,
and Dallner, G.
(1990)
J. Biol. Chem.
265,
1158-1164[Abstract/Free Full Text]
|
| 77.
|
Teclebrhan, H.,
Jakobsson-Borin, A.,
Brunk, U.,
and Dallner, G.
(1995)
Biochim. Biophys. Acta
1256,
157-165[Medline]
[Order article via Infotrieve]
|
| 78.
|
Momose, K.,
and Rudney, H.
(1972)
J. Biol. Chem.
247,
3930-3940[Abstract/Free Full Text]
|
| 79.
|
Trumpower, B. L.,
Houser, R. M.,
and Olson, R. E.
(1974)
J. Biol. Chem.
249,
3041-3048[Abstract/Free Full Text]
|
| 80.
|
Knox, C.,
Sase, E.,
Neupert, W.,
and Pines, O.
(1998)
J. Biol. Chem.
273,
25587-25593[Abstract/Free Full Text]
|
| 81.
|
Coque, J. J. R.,
Enguita, F. J.,
Martin, J. F.,
and Liras, P.
(1995)
J. Bacteriol.
177,
2230-2235[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Gulmezian, H. Zhang, G. T. Javor, and C. F. Clarke
Genetic Evidence for an Interaction of the UbiG O-Methyltransferase with UbiX in Escherichia coli Coenzyme Q Biosynthesis.
J. Bacteriol.,
September 1, 2006;
188(17):
6435 - 6439.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Cape, J. R. Strahan, M. J. Lenaeus, B. A. Yuknis, T. T. Le, J. N. Shepherd, M. K. Bowman, and D. M. Kramer
The Respiratory Substrate Rhodoquinol Induces Q-cycle Bypass Reactions in the Yeast Cytochrome bc1 Complex: MECHANISTIC AND PHYSIOLOGICAL IMPLICATIONS
J. Biol. Chem.,
October 14, 2005;
280(41):
34654 - 34660.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Johnson, P. Gin, B. N. Marbois, E. J. Hsieh, M. Wu, M. H. Barros, C. F. Clarke, and A. Tzagoloff
COQ9, a New Gene Required for the Biosynthesis of Coenzyme Q in Saccharomyces cerevisiae
J. Biol. Chem.,
September 9, 2005;
280(36):
31397 - 31404.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Marbois, P. Gin, K. F. Faull, W. W. Poon, P. T. Lee, J. Strahan, J. N. Shepherd, and C. F. Clarke
Coq3 and Coq4 Define a Polypeptide Complex in Yeast Mitochondria for the Biosynthesis of Coenzyme Q
J. Biol. Chem.,
May 27, 2005;
280(21):
20231 - 20238.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Gin and C. F. Clarke
Genetic Evidence for a Multi-subunit Complex in Coenzyme Q Biosynthesis in Yeast and the Role of the Coq1 Hexaprenyl Diphosphate Synthase
J. Biol. Chem.,
January 28, 2005;
280(4):
2676 - 2681.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W. Baba, G. I. Belogrudov, J. C. Lee, P. T. Lee, J. Strahan, J. N. Shepherd, and C. F. Clarke
Yeast Coq5 C-Methyltransferase Is Required for Stability of Other Polypeptides Involved in Coenzyme Q Biosynthesis
J. Biol. Chem.,
March 12, 2004;
279(11):
10052 - 10059.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Gin, A. Y. Hsu, S. C. Rothman, T. Jonassen, P. T. Lee, A. Tzagoloff, and C. F. Clarke
The Saccharomyces cerevisiae COQ6 Gene Encodes a Mitochondrial Flavin-dependent Monooxygenase Required for Coenzyme Q Biosynthesis
J. Biol. Chem.,
July 3, 2003;
278(28):
25308 - 25316.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Jonassen, B. N. Marbois, K. F. Faull, C. F. Clarke, and P. L. Larsen
Development and Fertility in Caenorhabditis elegans clk-1 Mutants Depend upon Transport of Dietary Coenzyme Q8 to Mitochondria
J. Biol. Chem.,
November 15, 2002;
277(47):
45020 - 45027.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Santos-Ocana, T. Q. Do, S. Padilla, P. Navas, and C. F. Clarke
Uptake of Exogenous Coenzyme Q and Transport to Mitochondria Is Required for bc1 Complex Stability in Yeast coq Mutants
J. Biol. Chem.,
March 22, 2002;
277(13):
10973 - 10981.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. L. Crane
Biochemical Functions of Coenzyme Q10
J. Am. Coll. Nutr.,
December 1, 2001;
20(6):
591 - 598.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Jonassen, P. L. Larsen, and C. F. Clarke
A dietary source of coenzyme Q is essential for growth of long-lived Caenorhabditis elegans clk-1 mutants
PNAS,
December 28, 2000;
(2000)
21337498.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
N. Uchida, K. Suzuki, R. Saiki, T. Kainou, K. Tanaka, H. Matsuda, and M. Kawamukai
Phenotypes of Fission Yeast Defective in Ubiquinone Production Due to Disruption of the Gene for p-Hydroxybenzoate Polyprenyl Diphosphate Transferase
J. Bacteriol.,
December 15, 2000;
182(24):
6933 - 6939.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
W. W. Poon, D. E. Davis, H. T. Ha, T. Jonassen, P. N. Rather, and C. F. Clarke
Identification of Escherichia coli ubiB, a Gene Required for the First Monooxygenase Step in Ubiquinone Biosynthesis
J. Bacteriol.,
September 15, 2000;
182(18):
5139 - 5146.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
T. Jonassen and C. F. Clarke
Isolation and Functional Expression of Human COQ3, a Gene Encoding a Methyltransferase Required for Ubiquinone Biosynthesis
J. Biol. Chem.,
April 21, 2000;
275(17):
12381 - 12387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Søballe and R. K. Poole
Ubiquinone limits oxidative stress in Escherichia coli
Microbiology,
April 1, 2000;
146(4):
787 - 796.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
T. Q. Do, A. Y. Hsu, T. Jonassen, P. T. Lee, and C. F. Clarke
A Defect in Coenzyme Q Biosynthesis Is Responsible for the Respiratory Deficiency in Saccharomyces cerevisiae abc1 Mutants
J. Biol. Chem.,
May 18, 2001;
276(21):
18161 - 18168.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Hihi, Y. Gao, and S. Hekimi
Ubiquinone Is Necessary for Caenorhabditis elegans Development at Mitochondrial and Non-mitochondrial Sites
J. Biol. Chem.,
January 11, 2002;
277(3):
2202 - 2206.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Jonassen, P. L. Larsen, and C. F. Clarke
A dietary source of coenzyme Q is essential for growth of long-lived Caenorhabditis elegans clk-1 mutants
PNAS,
January 16, 2001;
98(2):
421 - 426.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|